Skip to Content

Phospha 250 Neutral (potassium phosphate / sodium phosphate) Disease Interactions

There are 9 disease interactions with Phospha 250 Neutral (potassium phosphate / sodium phosphate):

Major

Alkalinizing agents (applies to Phospha 250 Neutral) sodium/water balance

Major Potential Hazard, Moderate plausibility. Applicable conditions: Hypernatremia, Fluid Retention

Alkalinizing agents containing sodium can induce sodium and water retention and result in hypernatremia, hypokalemia, hyperosmolality, edema and aggravation of congestive heart failure. Therapy with sodium- containing alkalinizing agents should not be used in patients with hypernatremia or fluid retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with alkalinizing agents is recommended.

References

  1. "Product Information. Sodium Bicarbonate (sodium bicarbonate)." Astra USA, Westborough, MA.
  2. "Product Information. Sodium Lactate (sodium lactate)." Abbott Pharmaceutical, Abbott Park, IL.
Major

Laxatives (applies to Phospha 250 Neutral) inflammatory bowel disease

Major Potential Hazard, Moderate plausibility.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

References

  1. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  2. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
Major

Laxatives (applies to Phospha 250 Neutral) intestinal obstruction disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

References

  1. "Product Information. Kondremul (mineral oil)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  3. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
  4. "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet, Lynchburg, VA.
  5. "Product Information. Fleet Babylax (glycerin)." Alcon Laboratorries Inc, Fort Worth, TX.
View all 5 references
Major

Phosphates (applies to Phospha 250 Neutral) hypocalcemia

Major Potential Hazard, High plausibility. Applicable conditions: Pancreatitis, Hyperkalemia, Renal Dysfunction, Pancreatitis, Hypoparathyroidism, Hyperkalemia, Phosphate Imbalance

The use of phosphates is in general contraindicated in conditions where high potassium, high phosphate, or low calcium may be encountered such as hypoparathyroidism, osteomalacia, acute pancreatitis, or chronic renal disease.

References

  1. "Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals, Tampa, FL.
  2. "Product Information. Fleet Enema (sodium biphosphate-sodium phosphate)." Fleet, Lynchburg, VA.
Major

Phosphates (applies to Phospha 250 Neutral) phosphate imbalance

Major Potential Hazard, High plausibility. Applicable conditions: Renal Dysfunction, Hypoparathyroidism

Therapy with phosphates should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment). Elevated serum concentrations of phosphate and calcium can exceed the solubility level and result in calcium-phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body. Clinical monitoring of serum calcium and phosphate concentrations is necessary.

References

  1. "Product Information. Fleet Enema (sodium biphosphate-sodium phosphate)." Fleet, Lynchburg, VA.
  2. "Product Information. K-Phos Neutral (potassium phosphate)." Beach Pharmaceuticals, Tampa, FL.
Major

Sodium phosphate (applies to Phospha 250 Neutral) electrolyte imbalance

Major Potential Hazard, High plausibility. Applicable conditions: Congestive Heart Failure, Dehydration, Phosphate Imbalance, Gastrointestinal Obstruction, Inflammatory Bowel Disease

The use of sodium phosphates is contraindicated in patients with congenital megacolon, intestinal obstruction, imperforate anus, active inflammatory disease or congestive heart failure. Serious, potentially life-threatening electrolyte imbalance such as hypocalcemia and hyperphosphatemia can result with prolonged or excessive use of phosphate laxatives. Hypernatremia and dehydration can occur due to improper dilution of hypertonic saline laxatives. Therapy with sodium phosphates should be administered cautiously and frequency of administration limited in patients with renal dysfunction, colostomy, cardiac dysfunction, or electrolyte imbalance. Clinical monitoring of electrolyte concentrations is recommended.

References

  1. "Product Information. Fleet Enema (sodium biphosphate-sodium phosphate)." Fleet, Lynchburg, VA.
  2. "Product Information. Magnesium Sulfate (magnesium sulfate)." Abbott Pharmaceutical, Abbott Park, IL.
Moderate

Potassium phosphate (applies to Phospha 250 Neutral) aluminum toxicity/renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Prematurity/Underweight in Infancy

Potassium phosphate injections contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration in patients with renal impairment. Preterm infants are particularly at risk for aluminum toxicity because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which also contain aluminum. Patients with renal impairment, including preterm infants, who receive greater than 4 to 5 mcg/kg/day of parenteral aluminum can accumulate aluminum to levels associated with central nervous system and bone toxicity. Potassium phosphate injection for parenteral nutrition is not recommended in adults weighing less than 45 kg or pediatric patients less than 12 years of age or weighing less than 40 kg due to the risks of aluminum toxicity.

Moderate

Potassium phosphate (applies to Phospha 250 Neutral) cardiac disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Heart Disease

Potassium phosphate injection may increase the risk of hyperkalemia. Patients with cardiac disease may be more susceptible to the effects of hyperkalemia. Caution is advised when using potassium phosphates in patients with heart disease. Continuous electrocardiographic (ECG) monitoring is recommended for higher infusion rates of potassium.

Moderate

Potassium phosphate (applies to Phospha 250 Neutral) hypomagnesemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Magnesium Imbalance, Hypercalcemia, Diabetic Ketoacidosis

Intravenous infusion of phosphate has been reported to cause a decrease in serum magnesium (and calcium) concentrations when administered to patients with hypercalcemia and diabetic ketoacidosis. Monitor serum magnesium concentrations during treatment. Caution is advised in patients with magnesium imbalances.

Phospha 250 Neutral (potassium phosphate / sodium phosphate) drug interactions

There are 67 drug interactions with Phospha 250 Neutral (potassium phosphate / sodium phosphate)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.